Future research should prioritize controlled clinical trials to confirm its efficacy and safety, as well as translational studies to uncover the interactions between the JAK1 signaling pathway and the pathogenesis of keratinizing disorders, especially in patients with EPPP/PK. This evidence concerns the gene JAK1 and keratinization disease.